Matthewabii Profile Banner
Matthew Abikenari Profile
Matthew Abikenari

@Matthewabii

Followers
67
Following
124
Media
1
Statuses
31

M.D. Candidate @stanfordmed | Clinical Neuroscience postgraduate @uniofoxford | U.S. Herbruck scholar of Oxford | focused on Neurosurgical Oncology

Stanford, CA
Joined September 2021
Don't wanna be here? Send us removal request.
@Matthewabii
Matthew Abikenari
10 days
Our recent work published in Cancers, GBM hijacks sphingolipid metabolism to exclude T cells & polarize macrophages. S1P traps CD8+ T cells in marrow, fuels M2 TAMs & angiogenesis leaving TME immunologically untouchable. @Ravi_Medikonda1 @StanfordNsurg .
Tweet media one
0
0
2
@Matthewabii
Matthew Abikenari
12 days
En collab. avec UCLA, nous montrons que des biomarqueurs périphériques (Aβ40/42) liés à la réponse immune sont associés à une meilleure mémoire subjective chez des femmes à risque, après yoga ou entraînement. Vers des marqueurs du risque #Alzheimers #AB40.
0
0
1
@Matthewabii
Matthew Abikenari
12 days
Check out our recent work on emergent CAR-T advances in neuro-Onc summarized by the fantastic Resident:/Mentor Ravi Medikonda!.
@JournalCancer
ACS Journal Cancer
12 days
What are the top advances in CAR-T cell therapy for neuro-oncology? This video featuring @Ravi_Medikonda1 and @MichaelLimMD summarizes the most significant recent advances. Read their in-depth overview: @OncoAlert @StanfordNsurg @Ethan_Schonfeld
0
0
1
@Matthewabii
Matthew Abikenari
1 month
Honored to share our @JournalCancer commentary on a .transformative year for CAR T in neuro-oncology—highlighting bivalent, BiTE-secreting, and synNotch CARs tackling GBM immunoresistance and DMG antigen escape. @StanfordNsurg @LimLab_Stanford.
@JournalCancer
ACS Journal Cancer
1 month
There have been several key advances in the past year regarding CAR T-cell immunotherapy in neuro-oncology. This new commentary from @MichaelLimMD & @StanfordNsurg colleagues highlights some significant recent advances: @OncoAlert @Ethan_Schonfeld
Tweet media one
1
0
4
@Matthewabii
Matthew Abikenari
1 month
Our latest in J Neuro-Oncology:.PIK3CA-mutant meningiomas may represent a hormone-driven, immunosuppressive subtype—where endocrine signaling intersects with PI3K-AKT-mTOR to shape TME. Endlessly grateful for my mentor and role model Dr. Michael Lim.
@jasonpsheehan
Jason Sheehan
2 months
In the Journal of Neuro-Oncology, the Stanford neurosurgery team studied PIK3CA-mutated meningiomas looking at targeted therapy approaches.
Tweet media one
0
0
2
@Matthewabii
Matthew Abikenari
1 month
RT @jasonpsheehan: In the Journal of Neuro-Oncology, the Stanford neurosurgery team studied PIK3CA-mutated meningiomas looking at targeted….
0
21
0
@Matthewabii
Matthew Abikenari
1 month
RT @StanfordNsurg: Stanford Neurosurgery is at #AANS2025!. Medical student, @Matthewabii presenting: Evaluating Surgical Outcomes of Microv….
0
2
0
@Matthewabii
Matthew Abikenari
1 year
RT @RitterLab: Killer T cells are beautiful! This high resolution/rapid acquisition video of a T cell attacking a lymphoma cancer cell was….
0
2K
0
@Matthewabii
Matthew Abikenari
3 years
RT @renefreichel: 1 | Can we use network analysis to understand the interactions between Cannabis-use-disorder symptoms? What does this te….
0
3
0
@Matthewabii
Matthew Abikenari
3 years
RT @renefreichel: So excited to have been part of this project. Global, far-reaching & meaningful insights - project led by @kairuggeri!.
0
1
0
@Matthewabii
Matthew Abikenari
4 years
There’s something so disheartening and arbitrary about life and identity. how me and my friends are eating Ethiopian food right now in LA, all the while, the Ethiopian government is deliberately starving it’s own civilians to death over the Ahmed’s conflict in Tigray. .
0
0
11
@Matthewabii
Matthew Abikenari
4 years
RT @EricTopol: In the United States, 400,000 covid deaths (of 700K) occurred after the 1st vaccines were given. Almost all of the last 200,….
0
1K
0
@Matthewabii
Matthew Abikenari
4 years
RT @renefreichel: New preprint - see important findings below! 🔔 Very excited to be part of this project!.
0
2
0